Sjögren's Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient.

Caeyman, Aaron; Vandekerckhove, Olivia; Pat, Karin; Wynants, Jokke; Weytjens, Karolien; de Wergifosse, Isabelle; Cuppens, Kristof

Caeyman, Aaron; Vandekerckhove, Olivia; Pat, Karin; Wynants, Jokke; Weytjens, Karolien; de Wergifosse, Isabelle; Cuppens, Kristof.

Afiliação

Caeyman A; Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
Vandekerckhove O; Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Pat K; Department of Respiratory Medicine and Thoracic Oncology, Jessa Hospital, Hasselt, Belgium.
Wynants J; Department of Respiratory Medicine and Thoracic Oncology, Jessa Hospital, Hasselt, Belgium.
Weytjens K; Department of Respiratory Medicine and Thoracic Oncology, Jessa Hospital, Hasselt, Belgium.
de Wergifosse I; Department of Rheumatology, Jessa Hospital, Hasselt, Belgium.
Cuppens K; Department of Respiratory Medicine and Thoracic Oncology, Jessa Hospital, Hasselt, Belgium.

Case Rep Oncol ; 16(1): 1095-1099, 2023.

Article em En | MEDLINE | ID: mdl-37900791

Palavras-chave

Case report; Immune checkpoint inhibition; Immune-related adverse event; Non-small cell lung carcinoma; Pembrolizumab; Sicca syndrome; Sjögren's syndrome

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Case Rep Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google